

Gemelli



Fondazione Policlinico Universitario A. Gemelli
Università Cattolica del Sacro Cuore

ART

Advanced Radiation
Therapy



What is the impact of high dose radiotherapy on survival and neurocognitive functions in naïve glioblastoma? A long term results of a prospective phase II study.

*S. Chiesa, G. Chiloiro, F. Beghella Bartoli, S. Luzi, M. Ferro, C. Mazzarella, L. Dinapoli, M. Massaccesi, V. Amato,
M.A. Gambacorta, V. Valentini, M. Balducci*

Fondazione Policlinico Universitario A. Gemelli, Dipartimento di Radioterapia Oncologica-Gemelli ART, Roma, Italy.




Il sottoscritto Francesco Beghella Bartoli

ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 17 del Reg. Applicativo dell'Accordo Stato-Regione del 5 novembre 2009,

dichiara

che negli ultimi due anni NON ha avuto rapporti diretti di finanziamento con soggetti portatori di interessi commerciali in campo sanitario

BACKGROUND



BTSG 69-01

BTSG 72-01

RTOG 74-01



BACKGROUND

CLINICAL INVESTIGATION

RELATIONSHIP BETWEEN NEUROCOGNITIVE FUNCTION AND QUALITY OF LIFE AFTER WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH BRAIN METASTASIS

JING LI, M.D., PH.D.,* SOREN M. BENTZEN, PH.D., D.Sc.,* JIALIANG LI, PH.D.,[†]
MARKUS RENSCHLER, M.D.,[‡] AND MINESH P. MEHTA, M.D.*

Brain

Neurocognitive function and QOL are correlated. Neurocognitive function scores from previous visits are predictive of QOL. **Neurocognitive function deterioration precedes QOL decline.** The sequential association between NCF and

A prospective study on neurocognitive effects after primary radiotherapy in high-grade glioma patients

The course of neurocognitive functioning in high-grade glioma patients¹

Ingeborg Bosma,² Maaike J. Vos, Jan J. Heimans,³ Martin J.B. Taphoorn, Neil K. Aaronson, Tjeerd J. Postma, Henk M. van der Ploeg, Martin Muller, W. Peter Vandertop, Ben. J. Slotman, and Martin Klein

Raphael Bodensohn¹ · Stefanie Corradini¹ · Ute Ganswindt¹ · Jan Hofmaier¹ ·
Oliver Schnell² · Claus Belka^{1,3,4} · Maximilian Niyazi^{1,3,4}

HGG patients showed a marked decline in neurocognitive functioning in the course of their disease. **Patients with tumor progression performed worse on neurocognitive**

Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy

Silvia Scoccianti · Beatrice Detti · Samantha Cipressi ·
Alberto Iannalifi · Ciro Franzese · Giampaolo Biti



AIMS/METHODS

Primary endpoint:

- Neurocognitive function evaluation



Secondary endpoints:

- Overall Survival (OS)
- Progression free survival (PFS)

CRITERY ELIGIBILITY

- SVV $\geq 14,6$ mo
- CTV ≤ 8 cm
- GBM
- Patients (≥ 18 yrs)

METHODS



Total dose:
6940 cGy

Patients' characteristics

	Group A n=22	Group B n=16
Age (years)		
• Median	54	56
• Range	34-72	25-65
Sex (n)		
• Male	13	10
• Female	9	6
Type of surgery (n)		
• Subtotal resection	16	10
• Total resection	6	6
RPA class (n)		
• I	4	2
• III	5	4
• IV	13	10

METHODS



OS ≥ 14.6 mth

Società Italiana di Radiobiologia
MATERIALE NON RIPRODUCIBILE

METHODS

The Mini-Mental State Exam

Patient _____ Examiner _____ Date _____

Maximum Score

Orientation

- 5 () What is the (year) (season) (date) (day) (month)?
5 () Where are we (state) (country) (town) (hospital) (floor)?

Registration

- 3 () Name 3 objects: 1 second to say each. Then ask the patient all 3 after you have said them. Give 1 point for each correct answer. Then repeat them until he/she learns all 3. Count trials and record.
Trials _____

Attention and Calculation


- 5 () Serial 7's. 1 point for each correct answer. Stop after 5 answers.
Alternatively spell "world" backward.

Recall

- 3 () Ask for the 3 objects repeated above. Give 1 point for each correct answer.

Language

- 2 () Name a pencil and watch.
1 () Repeat the following "No ifs, ands, or buts"
3 () Follow a 3-stage command:
"Take a paper in your hand, fold it in half, and put it on the floor."
1 () Read and obey the following: CLOSE YOUR EYES
1 () Write a sentence.
1 () Copy the design shown.



Total Score _____

ASSESS level of consciousness along a continuum _____
Alert Drowsy Stupor Coma

RAB
Società Italiana di Radiobiologia
MATERIALE NON RIPRODUCIBILE



RESULTS

11/38pts
OS ≥ 14.6 mth



The Mini-Mental State Exam

Patient _____ Examiner _____ Date _____

Maximum Score

5 () Orientation
What is the (year) (season) (date) (day) (month)?
Where are we (state) (country) (town) (hospital) (floor)?

TS: 10

TS: 9,6/10

3 () Registration
Name 3 objects: 1 second to say each. Then ask the patient all 3 after you have said them. Give 1 point for each correct answer. Then repeat them until he/she learns all 3. Count trials and record.
Trials _____

TS: 3

TS: 3/3

5 () Attention and Calculation
Serial 7's. 1 point for each correct answer. Stop after 5 answers.
Alternatively spell "world" backward.

TS: 5

TS: 4,1/5

3 () Recall
Ask for the 3 objects repeated above. Give 1 point for each correct answer.


TS: 3

TS: 2,2/3

2 () Language
Name a pencil and watch.
Repeat the following "No ifs, ands, or buts"
Follow a 3-stage command:
"Take a paper in your hand, fold it in half, and put it on the floor."
Read and obey the following: CLOSE YOUR EYES
Write a sentence.
Copy the design shown.

TS: 8

TS: 8/8



TS: 1

TS: 0,9/1

TS:
30

TS:
27,9/30



Total Score _____
ASSESS level of consciousness along a continuum _____
Alert Drowsy Stupor Coma

5 pts Without recurrence	6 pts With recurrence
TS: 28,9	TS: 25,7
P value= 0,02	



RESULTS

Tot: 38 pts	M: 23 (60%)	F: 15 (40%)
Median Age	56 years (range 25-72 yrs)	
Median FUP	77 months (25-87 mo)	



Limitations

- Lack of baseline evaluation
- Sample size



Take home message

- Better outcome when **high doses** are used in combination with TMZ, without an increase of toxicity (no detrimental in NCF were observed)
- Tumor progression, may be the most important factor for the neurological deterioration



Grazie per l'attenzione

